Medical Outcomes Liaison
Boost your chances before you apply.
Alumis
South San Francisco, CA, US
Summary
Engage payers and healthcare decision makers to communicate the clinical and economic value of therapies to support formulary access and reimbursement. Translate clinical and HEOR evidence into value narratives to support pre-launch and launch readiness.
Job Description
Alumis Inc. is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Even with treatment innovations of the last two decades, many patients with immunologic conditions continue to suffer - our goal is to fundamentally change the outcomes for these patients.
The Medical Outcomes Liaison (MOL) is a field-based Medical Affairs professional responsible for engaging payers and healthcare decision makers (HCDMs). This role focuses on communicating the clinical and economic value of Alumis therapies to support formulary access, reimbursement, and patient outcomes. This is a critical role supporting pre-launch and launch readiness, translating clinical and HEOR evidence into meaningful value narratives for population-based stakeholders.
Key Responsibilities:
- Build and maintain relationships with payers, PBMs, and health systems
- Deliver clinical, real-world, and health economic evidence to inform access decisions
- Support payer engagement strategy, including pre-launch activities and value communication
- Contribute to HEOR and evidence generation plans, including AMCP dossier support
- Gather insights on payer needs and market dynamics to inform strategy
- Collaborate cross-functionally with Medical Affairs, HEOR, and Market Access teams
Qualifications:
- Advanced degree required (PharmD, PhD, MD, MPH, or equivalent)
- 5+ years of experience in Medical Affairs, HEOR, Market Access, or related field
- Experience engaging payers or healthcare decision makers strongly preferred
- Strong understanding of HEOR, RWE, and U.S. payer landscape
- Excellent communication and stakeholder engagement skills
What You Bring:
- Ability to translate complex data into clear, payer-relevant value insights
- Strong collaboration skills in a cross-functional, fast-paced environment
- Strategic mindset with a focus on value-based care and patient access
Why Join Alumis
- Be part of a launch-stage biotech shaping the future of TYK2 inhibition
- Play a key role in defining the value story for a novel therapy
- Work in a highly collaborative, science-driven Medical Affairs organization
This position is primarily remote with travel up to roughly 50–75% We have 3 MOL roles (geographically dispersed) that we are working to fill.
The salary range for this position is $200,00 USD to 265,000 USD annually. This salary range is an estimate, and the actual salary may very based on the Company’s compensation practices degree and background.
Alumis compensation packages include generous stock option grants for all employees as well as an annual bonus program.
Other benefits include:
- Health insurance premiums paid at 90% for employee, 80% for dependents
- Free access to Genentech Bus & Ferry Share program
- $100 monthly cell phone stipend
- Unlimited PTO for Exempt employees
- Free onsite gym and a kitchen stocked with yummy snacks and drinks!
We are a hard-working, collaborative team on a mission to transform patient’s lives-- and we aspire to elevate, challenge and nurture one another along the way.
Alumis Inc. is an equal opportunity employer.
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects.
Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction.
Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.
Founded
2021
Company size
51-200 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
South San Francisco, California
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects.
Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction.
Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.
Founded
2021
Company size
51-200 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
South San Francisco, California